Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Szepfalusi, Z; Horak Jr, F; Eiwegger, T; Horak, E; Huttegger, I; Wolf-Abdolvahab, S; Varga, EM; Riedler, J.
Allergen-specific immunotherapy for IgE-mediated diseases in childhood and adolescence. Overview of approved allergen products in Austria-Update 2017
MONATSSCHR KINDERH. 2019; 167: S1-S21.
Doi: 10.1007/s00112-018-0448-8
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Varga Eva-Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The consensus report from 2009 on allergen-specific immunotherapy for immunoglobulin E (IgE) mediated allergic diseases in childhood and adolescence was issued due to the increasingly large offer of allergen preparations and the heterogeneous state of studies. The field of immunotherapy has now undergone a clear restructuring (Regulations of the European Union [EU], Therapy-Allergens Regulations etc.). There remains the ethical obligation to treat children and adolescents with allergen preparations, which were also tested in studies including children and adolescents and were classified as being effective and safe (EU regulative, European Medicines Agency [EMA]). The updated list from 2017 of immunotherapy preparations with particular reference to children and adolescents valid for Austria has now been adapted. A critical appraisal of the study situation has been carried out again. Some immunotherapy products which have recently come onto the market show an improved dataset from studies that were carried out exclusively on children and adolescents. These approved and licensed products can therefore be recommended for indications-compliant administration to children and adolescents.
- Find related publications in this database (Keywords)
- Hypersensitivity
- Immunologic desensitization
- Sublingual immunotherapy
- Subcutaneous injections
- State of-the-art review